Emergent BioSolutions to Participate in October 2010 Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)-- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be participating in the following investor conferences in October 2010.

  • The 9th Annual BIO Investor Forum
    San Francisco, CA.
    October 5, 2010
    Corporate Overview Presentation
    9:00 AM Pacific
    [The presentation, which will include a discussion of the Company’s business activities, financial outlook and current news, will be webcast live.]
  • The 17th Annual BioCentury/Thomson Reuters Newsmakers in the Biotech Industry Conference
    New York, NY.
    October 22, 2010
    Corporate Overview Presentation
    2:00 PM Eastern
    [The presentation, which will include a discussion of the Company’s business activities, financial outlook and current news, will be webcast live.]

Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.



CONTACT:

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
[email protected]
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
[email protected]

KEYWORDS:   United States  North America  California  Maryland  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”